Skip to main content
Top
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Research

Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis

Authors: Shah Jahan, Saba Khaliq, Bushra Ijaz, Waqar Ahmad, Sajida Hassan

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

Background

Hepatitis C virus (HCV) Core protein is thought to trigger activation of multiple signaling pathways and play a significant role in the alteration of cellular gene expression responsible for HCV pathogenesis leading to hepatocellular carcinoma (HCC). However, the exact molecular mechanism of HCV genome specific pathogenesis remains unclear. We examined the in vitro effects of HCV Core protein of HCV genotype 3a and 1a on the cellular genes involved in oxidative stress and angiogenesis. We also studied the ability of HCV Core and Cox-2 siRNA either alone or in combination to inhibit viral replication and cell proliferation in HCV serum infected Huh-7 cells.

Results

Over expression of Core gene of HCV 3a genotype showed stronger effect in regulating RNA and protein levels of Cox-2, iNOS, VEGF, p-Akt as compared to HCV-1a Core in hepatocellular carcinoma cell line Huh-7 accompanied by enhanced PGE2 release and cell proliferation. We also observed higher expression levels of above genes in HCV 3a patient's blood and biopsy samples. Interestingly, the Core and Cox-2-specific siRNAs down regulated the Core 3a-enhanced expression of Cox-2, iNOS, VEGF, p-Akt. Furthermore, the combined siRNA treatment also showed a dramatic reduction in viral titer and expression of these genes in HCV serum-infected Huh-7 cells. Taken together, these results demonstrated a differential response by HCV 3a genotype in HCV-induced pathogenesis, which may be due to Core and host factor Cox-2 individually or in combination.

Conclusions

Collectively, these studies not only suggest a genotype-specific interaction between key players of HCV pathogenesis but also may represent combined viral and host gene silencing as a potential therapeutic strategy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Giannini C, Brechot C: Hepatitis C virus biology. Cell Death Differ 2003, 10: S27-S38. 10.1038/sj.cdd.4401121CrossRefPubMed Giannini C, Brechot C: Hepatitis C virus biology. Cell Death Differ 2003, 10: S27-S38. 10.1038/sj.cdd.4401121CrossRefPubMed
2.
go back to reference Raja NS, Janjua KA: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008, 41: 4-8.PubMed Raja NS, Janjua KA: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008, 41: 4-8.PubMed
3.
go back to reference Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, et al.: HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol 2010, 16: 4321-4328. 10.3748/wjg.v16.i34.4321PubMedCentralCrossRefPubMed Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, et al.: HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol 2010, 16: 4321-4328. 10.3748/wjg.v16.i34.4321PubMedCentralCrossRefPubMed
4.
go back to reference Okuda M, Li K, Beard MR, et al.: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122: 568-57/1. 10.1053/gast.2002.30983CrossRef Okuda M, Li K, Beard MR, et al.: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122: 568-57/1. 10.1053/gast.2002.30983CrossRef
5.
go back to reference Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al.: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4: 1065-1067. 10.1038/2053CrossRefPubMed Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al.: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4: 1065-1067. 10.1038/2053CrossRefPubMed
6.
go back to reference Tardif KD, Waris G, Siddiqui A: Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005, 13: 159-163. 10.1016/j.tim.2005.02.004CrossRefPubMed Tardif KD, Waris G, Siddiqui A: Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005, 13: 159-163. 10.1016/j.tim.2005.02.004CrossRefPubMed
7.
go back to reference Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, et al.: Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53: 1665-1672. 10.1136/gut.2003.038364PubMedCentralCrossRefPubMed Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, et al.: Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53: 1665-1672. 10.1136/gut.2003.038364PubMedCentralCrossRefPubMed
8.
go back to reference Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al.: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999, 29: 688-696. 10.1002/hep.510290355CrossRefPubMed Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al.: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999, 29: 688-696. 10.1002/hep.510290355CrossRefPubMed
9.
go back to reference Rahman MA, Kohno H, Nagasue N: COX-2 - a target for preventing hepatic carcinoma? Expert Opin Ther Targets 2002, 6: 483-490. 10.1517/14728222.6.4.483CrossRefPubMed Rahman MA, Kohno H, Nagasue N: COX-2 - a target for preventing hepatic carcinoma? Expert Opin Ther Targets 2002, 6: 483-490. 10.1517/14728222.6.4.483CrossRefPubMed
10.
go back to reference Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998, 2: 715-719.PubMed Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998, 2: 715-719.PubMed
11.
go back to reference Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT, et al.: Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004, 24: 853-860.PubMed Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT, et al.: Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004, 24: 853-860.PubMed
12.
go back to reference Tang TC, Poon RT, Lau CP, Xie D, Fan ST: Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005, 11: 1896-1902.PubMedCentralCrossRefPubMed Tang TC, Poon RT, Lau CP, Xie D, Fan ST: Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005, 11: 1896-1902.PubMedCentralCrossRefPubMed
13.
go back to reference Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38: 756-768. 10.1053/jhep.2003.50380CrossRefPubMed Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38: 756-768. 10.1053/jhep.2003.50380CrossRefPubMed
15.
go back to reference Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2: 489-501. 10.1038/nrc839CrossRefPubMed Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2: 489-501. 10.1038/nrc839CrossRefPubMed
16.
go back to reference Vidali M, Stewart SF, Albano E: Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. Trends Mol Med 2008, 14: 63-71. 10.1016/j.molmed.2007.12.005CrossRefPubMed Vidali M, Stewart SF, Albano E: Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. Trends Mol Med 2008, 14: 63-71. 10.1016/j.molmed.2007.12.005CrossRefPubMed
17.
go back to reference Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Pervais A, et al.: Inhibition of Core gene of HCV 3a genotype using synthetic and vector derived siRNAs. Virology J 2010, 7: 318. 10.1186/1743-422X-7-318CrossRef Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Pervais A, et al.: Inhibition of Core gene of HCV 3a genotype using synthetic and vector derived siRNAs. Virology J 2010, 7: 318. 10.1186/1743-422X-7-318CrossRef
18.
go back to reference Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, et al.: Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009, 15: 5080-5085. 10.3748/wjg.15.5080PubMedCentralCrossRefPubMed Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, et al.: Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009, 15: 5080-5085. 10.3748/wjg.15.5080PubMedCentralCrossRefPubMed
19.
go back to reference Raza SA, Clifford GM, Franceschi S: Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007, 96: 1127-1134. 10.1038/sj.bjc.6603649PubMedCentralCrossRefPubMed Raza SA, Clifford GM, Franceschi S: Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007, 96: 1127-1134. 10.1038/sj.bjc.6603649PubMedCentralCrossRefPubMed
20.
go back to reference Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, et al.: Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 2009, 30: 554-559. 10.1111/j.1478-3231.2009.02164.xCrossRefPubMed Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, et al.: Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 2009, 30: 554-559. 10.1111/j.1478-3231.2009.02164.xCrossRefPubMed
21.
go back to reference Jackel-Cram C, Babiuk LA, Liu Q: Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007, 46: 999-1008. 10.1016/j.jhep.2006.10.019CrossRefPubMed Jackel-Cram C, Babiuk LA, Liu Q: Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007, 46: 999-1008. 10.1016/j.jhep.2006.10.019CrossRefPubMed
22.
go back to reference Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, et al.: Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 2007, 80: 484-492. 10.1016/j.lfs.2006.09.038CrossRefPubMed Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, et al.: Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 2007, 80: 484-492. 10.1016/j.lfs.2006.09.038CrossRefPubMed
23.
go back to reference Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K: Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 2000, 273: 485-491. 10.1006/bbrc.2000.2969CrossRefPubMed Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K: Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 2000, 273: 485-491. 10.1006/bbrc.2000.2969CrossRefPubMed
24.
go back to reference Gallo O, Franhi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al.: Cyclooxygenase-2 pathway Correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001, 3: 53-61. 10.1038/sj.neo.7900127PubMedCentralCrossRefPubMed Gallo O, Franhi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al.: Cyclooxygenase-2 pathway Correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001, 3: 53-61. 10.1038/sj.neo.7900127PubMedCentralCrossRefPubMed
25.
go back to reference Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N: Characteristic mutations in hepatitis virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci 2009, 100: 2465-2468. 10.1111/j.1349-7006.2009.01338.xCrossRefPubMed Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N: Characteristic mutations in hepatitis virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci 2009, 100: 2465-2468. 10.1111/j.1349-7006.2009.01338.xCrossRefPubMed
26.
go back to reference Pazienza V, Vinciguerra M, Andriulli A, Mangia A: Hepatitis C Virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 2010, 91: 1678-1686. 10.1099/vir.0.020644-0CrossRefPubMed Pazienza V, Vinciguerra M, Andriulli A, Mangia A: Hepatitis C Virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 2010, 91: 1678-1686. 10.1099/vir.0.020644-0CrossRefPubMed
27.
go back to reference Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, et al.: The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007, 56: 1302-1308. 10.1136/gut.2006.108647PubMedCentralCrossRefPubMed Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, et al.: The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007, 56: 1302-1308. 10.1136/gut.2006.108647PubMedCentralCrossRefPubMed
28.
go back to reference Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM: Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 2008, 197: 283-291. 10.1086/524846PubMedCentralCrossRefPubMed Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM: Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 2008, 197: 283-291. 10.1086/524846PubMedCentralCrossRefPubMed
29.
go back to reference Mann AE, Stanford S, Sherman EK: Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kB activation. Virus Research 2006, 121: 51-57. 10.1016/j.virusres.2006.04.001CrossRefPubMed Mann AE, Stanford S, Sherman EK: Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kB activation. Virus Research 2006, 121: 51-57. 10.1016/j.virusres.2006.04.001CrossRefPubMed
30.
go back to reference Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P: Increased intrahepatic cyclooxygenase, matrix metalloproteinase, and matrix metalloproteinase expression is associated with progressive liver disease in chronic hepatitis C Virus infection: role of viral core and NS5A proteins. Gut 2004, 53: 1665-1672. 10.1136/gut.2003.038364PubMedCentralCrossRefPubMed Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P: Increased intrahepatic cyclooxygenase, matrix metalloproteinase, and matrix metalloproteinase expression is associated with progressive liver disease in chronic hepatitis C Virus infection: role of viral core and NS5A proteins. Gut 2004, 53: 1665-1672. 10.1136/gut.2003.038364PubMedCentralCrossRefPubMed
31.
go back to reference Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al.: Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009, 81: 1032-1039. 10.1002/jmv.21473CrossRefPubMed Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al.: Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009, 81: 1032-1039. 10.1002/jmv.21473CrossRefPubMed
32.
go back to reference Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al.: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48: 372-380. 10.1159/000086064CrossRefPubMed Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al.: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48: 372-380. 10.1159/000086064CrossRefPubMed
33.
go back to reference Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al.: Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007, 81: 8211-8224. 10.1128/JVI.00487-07PubMedCentralCrossRefPubMed Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al.: Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007, 81: 8211-8224. 10.1128/JVI.00487-07PubMedCentralCrossRefPubMed
34.
go back to reference Kim M, Shin D, Kim SI, Park M: Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res 2006, 122: 1-10. 10.1016/j.virusres.2006.05.003CrossRefPubMed Kim M, Shin D, Kim SI, Park M: Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res 2006, 122: 1-10. 10.1016/j.virusres.2006.05.003CrossRefPubMed
35.
go back to reference Liu M, Ding H, Zhao P, Qin ZL, Gao J, Cao MM, et al.: RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci Biotechnol Biochem 2006, 70: 2049-2055. 10.1271/bbb.60001CrossRefPubMed Liu M, Ding H, Zhao P, Qin ZL, Gao J, Cao MM, et al.: RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci Biotechnol Biochem 2006, 70: 2049-2055. 10.1271/bbb.60001CrossRefPubMed
36.
go back to reference Buck M: Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 2008, 3: e2660. 10.1371/journal.pone.0002660PubMedCentralCrossRefPubMed Buck M: Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 2008, 3: e2660. 10.1371/journal.pone.0002660PubMedCentralCrossRefPubMed
37.
go back to reference el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, et al.: HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006, 12: 4836-4842.PubMedCentralPubMed el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, et al.: HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006, 12: 4836-4842.PubMedCentralPubMed
38.
go back to reference Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al.: Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 2007, 170: 478-489. 10.2353/ajpath.2007.060789PubMedCentralCrossRefPubMed Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al.: Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 2007, 170: 478-489. 10.2353/ajpath.2007.060789PubMedCentralCrossRefPubMed
39.
go back to reference Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al.: Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82: 569-574. 10.1128/JVI.01443-07PubMedCentralCrossRefPubMed Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al.: Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82: 569-574. 10.1128/JVI.01443-07PubMedCentralCrossRefPubMed
40.
41.
go back to reference Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S: Inhibition of HCV 3a genotype by siRNAs targeting envelope genes. Arch Virol 2010,156(3):433-442. 10.1007/s00705-010-0887-6CrossRefPubMed Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S: Inhibition of HCV 3a genotype by siRNAs targeting envelope genes. Arch Virol 2010,156(3):433-442. 10.1007/s00705-010-0887-6CrossRefPubMed
42.
go back to reference Henry SD, van der WP, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ: Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006, 14: 485-493. 10.1016/j.ymthe.2006.04.012CrossRefPubMed Henry SD, van der WP, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ: Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006, 14: 485-493. 10.1016/j.ymthe.2006.04.012CrossRefPubMed
43.
go back to reference Korf M, Jarczak D, Beger C, Manns MP, Kruger M: Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 2005, 43: 225-234. 10.1016/j.jhep.2005.02.046CrossRefPubMed Korf M, Jarczak D, Beger C, Manns MP, Kruger M: Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 2005, 43: 225-234. 10.1016/j.jhep.2005.02.046CrossRefPubMed
44.
go back to reference Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M: Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 2007, 353: 882-888. 10.1016/j.bbrc.2006.12.117CrossRefPubMed Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M: Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 2007, 353: 882-888. 10.1016/j.bbrc.2006.12.117CrossRefPubMed
45.
go back to reference Randall G, Grakoui A, Rice CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 2003, 100: 235-240. 10.1073/pnas.0235524100PubMedCentralCrossRefPubMed Randall G, Grakoui A, Rice CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 2003, 100: 235-240. 10.1073/pnas.0235524100PubMedCentralCrossRefPubMed
46.
go back to reference Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9: 347-351. 10.1038/nm828CrossRefPubMed Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9: 347-351. 10.1038/nm828CrossRefPubMed
47.
go back to reference Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, et al.: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003, 100: 7797-7802. 10.1073/pnas.1330920100PubMedCentralCrossRefPubMed Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, et al.: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003, 100: 7797-7802. 10.1073/pnas.1330920100PubMedCentralCrossRefPubMed
48.
go back to reference Lemon SM, Lerat H, Weinman SA, Honda M: A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. Trans Am Clin Climatol Assoc 2000, 111: 146-156.PubMedCentralPubMed Lemon SM, Lerat H, Weinman SA, Honda M: A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. Trans Am Clin Climatol Assoc 2000, 111: 146-156.PubMedCentralPubMed
49.
go back to reference Lerat H, Honda M, Beard MR, et al.: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122: 352-365. 10.1053/gast.2002.31001CrossRefPubMed Lerat H, Honda M, Beard MR, et al.: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122: 352-365. 10.1053/gast.2002.31001CrossRefPubMed
50.
go back to reference Ohata K, Hamasaki K, Toriyama K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97: 3036-3043. 10.1002/cncr.11427CrossRefPubMed Ohata K, Hamasaki K, Toriyama K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97: 3036-3043. 10.1002/cncr.11427CrossRefPubMed
51.
go back to reference Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78: 1527-1531.CrossRefPubMed Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78: 1527-1531.CrossRefPubMed
52.
go back to reference Kato T, Miyamoto M, Date T, et al.: Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci 2003, 94: 679-68. 10.1111/j.1349-7006.2003.tb01502.xCrossRefPubMed Kato T, Miyamoto M, Date T, et al.: Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci 2003, 94: 679-68. 10.1111/j.1349-7006.2003.tb01502.xCrossRefPubMed
Metadata
Title
Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis
Authors
Shah Jahan
Saba Khaliq
Bushra Ijaz
Waqar Ahmad
Sajida Hassan
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-155

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine